Register entry
Amryt Pharmaceuticals Designated Activity Company
Data as of · How to read this entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 0
- Countries
- 0
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Mycapssa | Octreotide | capsule, delayed release, oral | 69880-120NDA |
Compare
Other companies listing octreotide
- USV Private Limited3 sites · 43 NDC
- Bachem Americas, Inc.2 sites · 26 NDC
- Chiesi USA, Inc.1 site · 25 NDC
- BCN Peptides SA1 site · 15 NDC
- Ambiopharm, Inc.1 site · 11 NDC
- LSNE, Inc.0 sites · 13 NDC
Enquiry
Common questions
- Is Amryt Pharmaceuticals Designated Activity Company FDA approved?
- Amryt Pharmaceuticals Designated Activity Company holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Amryt Pharmaceuticals Designated Activity Company make?
- 1 product is listed under Amryt Pharmaceuticals Designated Activity Company in the openFDA NDC Directory, most often as capsule, delayed release. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.